FDA工作人员对疗效提出质疑,Replimune皮肤癌疗法前景堪忧,盘前股价重挫25%

美股速递
Jul 28

FDA工作人员对Replimune Group Inc.旗下皮肤癌治疗方案的疗效提出质疑,引发市场剧烈反应——该公司盘前股价应声暴跌25%,跌幅令人咋舌。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10